APAX Apax Global Alpha

Hardman & Co Research on Apax Global Alpha (APAX) 2023 Capital Markets Day: accessing hidden gems

Hardman & Co Research
Hardman & Co Research on Apax Global Alpha (APAX) 2023 Capital Markets Day: accessing hidden gems

05-Jul-2023 / 15:50 GMT/BST
The issuer is solely responsible for the content of this announcement.


Hardman & Co Research on Apax Global Alpha (APAX)

2023 Capital Markets Day: accessing hidden gems

 

The key takeaway from AGA’s 27 June (CMD) was that 84% of value creation comes from operational improvements that APAX makes in the investee companies. On average, under APAX’s ownership, revenue growth accelerates by 700bps, EBITDA growth 1,500bps and the EBITDA margin 700bps. Additionally, the day highlighted that i) AGA gives access to companies unavailable elsewhere, ii) its companies are growing and performing well, iii) it is an All Weather Investment, with 84% of value creation under the manager’s control, iv) it has a robust balance sheet, and v) the 5%-of-NAV dividend has more value when the shares are at a big discount. Given the long-term NAV outperformance, the discount appears anomalous.

 

Please click on the link below for the full report:

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
1 Frederick’s Place

London

EC2R 8AE

Follow us on Twitter @HardmanandCo

Contact:

Mark Thomas



+44(0)203 693 7075

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1673539  05-Jul-2023 

fncls.ssp?fn=show_t_gif&application_id=1673539&application_name=news&site_id=research_pool
EN
05/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apax Global Alpha

Mark Thomas ... (+3)
  • Mark Thomas
  • Mike Foster
  • Richard Jeans

Hardman & Co Monthly: June 2025

Feature article: Addressing the “risk off” investment challenge As we approach mid-2025, life remains challenging for many UK companies and their shareholders, and ‒ as a broad generalisation – consensus suggests little will change in the foreseeable future. So, are we now facing a real risk of the UK economy stagnating due to lack of funding? If that is the case, who is going to take the initiative and avert such a crisis? Business life must continue, despite the macro environment providing ...

Brian Moretta ... (+3)
  • Brian Moretta
  • Jason Streets
  • Mark Thomas

Hardman & Co Monthly: May 2025

Feature article: Attractive asset managers - Radical derating presumes things only get worse The UK asset management sector has been significantly derated over the past couple of years. It has faced the dual problem of a shift towards passives and to private assets and away from traditional listed equities and bonds. However, the sector’s assets haven’t collapsed; its margins have proved relatively robust and its profits fairly stable, even against all the rising costs. The clear implication, ...

Mark Thomas
  • Mark Thomas

Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today

AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (no longer a core sector), and one portfolio company in particular, meant the strong average investee company EBITDA growth did not fuel NAV growth. However, the detail in the results bodes well, with i) investee companies deliveri...

 PRESS RELEASE

Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and...

Hardman & Co Research Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today 02-Apr-2025 / 11:39 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Apax Global Alpha (APAX): Jam yesterday, and tomorrow, but not today   AGA was transparent in that 2024 was a below-average year for the company, with a total NAV return of 0.8% (-3.0% constant currency, including a 4Q total NAV return of 2.6% (-1.8% cc). By comparison, the five-year total NAV CAGR return was 8.3%. Problems in healthcare (...

Mark Thomas ... (+2)
  • Mark Thomas
  • Martin Hall

Hardman & Co Monthly: April 2025

Feature article: 2024 pharma statistics An efficient reporting system has seen all the listed multinational pharmaceutical companies announce results for 2024, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of global pharmaceutical market growth plus the global and US company rankings for 2024. The year was characterised by 9.2% underlying (ex-COVID-19) growth. Much of the growth was driven by recently launched ant...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch